Get the Stockscreener App
2.65
1.85%
-0.05
After Hours:
2.69
0.04
+1.51%
Neuronetics Inc stock is traded at $2.65, with a volume of 973.29K.
It is down -1.85% in the last 24 hours and down -2.93% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$2.70
Open:
$2.69
24h Volume:
973.29K
Relative Volume:
0.73
Market Cap:
$175.23M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-2.2458
EPS:
-1.18
Net Cash Flow:
$-39.26M
1W Performance:
-15.06%
1M Performance:
-2.93%
6M Performance:
-39.50%
1Y Performance:
+157.28%
1-Day Range:
$2.61
$2.745
1-Week Range:
$2.61
$3.1673
52-Week Range:
$0.52
$5.92
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
2.65 | 178.54M | 69.23M | -33.10M | -39.26M | -1.18 |
|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.88B | 1.34B | 577.90M | 2.3455 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Real time alert setup for Neuronetics Inc. performanceEntry Point & Long-Term Safe Investment Plans - newser.com
Is Neuronetics Inc. (NRC) stock a buy before earnings results2025 Stock Rankings & Long-Term Investment Growth Plans - newser.com
What does recent volatility data suggest for Neuronetics Inc.Short Setup & AI Powered Market Trend Analysis - newser.com
Will Neuronetics Inc. bounce back from current supportTrade Volume Report & Long-Term Safe Investment Ideas - newser.com
Will Neuronetics Inc. continue its uptrendWeekly Stock Summary & AI Forecast Swing Trade Picks - newser.com
Sentiment analysis tools applied to Neuronetics Inc.July 2025 Patterns & AI Forecast Swing Trade Picks - newser.com
Will Neuronetics Inc. stock maintain dividend yieldWeekly Gains Report & Verified Momentum Stock Alerts - newser.com
Analyzing net buyer seller activity in Neuronetics Inc.July 2025 Institutional & Verified Trade Idea Suggestions - newser.com
Is Neuronetics Inc. stock a top momentum playJuly 2025 Earnings & Trade Opportunity Analysis - newser.com
Detecting support and resistance levels for Neuronetics Inc.Profit Target & Low Risk Entry Point Guides - newser.com
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Neuronetics (NASDAQ: STIM) grants 38,850 RSUs to 12 employees under Nasdaq 5635(c)(4) - Stock Titan
Exit strategy if you’re trapped in Neuronetics Inc.2025 Trading Volume Trends & Comprehensive Market Scan Insights - newser.com
Can trapped investors hope for a rebound in Neuronetics Inc.Volume Spike & Risk Managed Trade Strategies - newser.com
Neuronetics Inc. stock trend forecast2025 Market Overview & Fast Moving Market Watchlists - newser.com
Will Neuronetics Inc. stock maintain growth storyJuly 2025 Outlook & Fast Exit/Entry Strategy Plans - newser.com
Is Neuronetics Inc. stock attractive for long term wealth buildingRecession Risk & Target Return Focused Picks - newser.com
Neuronetics signs exclusive TMS device agreement with Elite DNA - Investing.com
Neuronetics signs exclusive TMS device agreement with Elite DNA By Investing.com - Investing.com Canada
Neuronetics (STIM) Secures Exclusive Deal with Elite DNA Behavio - GuruFocus
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence - The Manila Times
Neuronetics (NASDAQ: STIM) sole TMS provider to Elite DNA’s 30+ sites in 3‑year pact - Stock Titan
Neuronetics Revises Financial Results for Q4 and Full Year 2024 - MSN
Neuronetics (STIM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Is Neuronetics Inc. stock positioned well for digital economyJuly 2025 Decliners & Expert Verified Movement Alerts - fcp.pa.gov.br
Is the Valuation of Mauria Udyog Limited Sustainable P E and PEG BreakdownReal-Time Stock Alerts & Free High Yield Market Plays - earlytimes.in
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
14.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):